Documentation scienceplus.abes.fr version Bêta

À propos de : ▼Teriparatide for postmenopausal osteoporosis        

AttributsValeurs
type
Is Part Of
Subject
Title
  • ▼Teriparatide for postmenopausal osteoporosis
has manifestation of work
Abstract
  • ▼Teriparatide (Forsteo - Eli Lilly) is the first parathyroid hormone derivative to be licensed for the treatment of women with postmenopausal osteoporosis. It is described as a "bone-formation agent",1 in contrast to established treatments, such as bisphosphonates, raloxifene, calcitriol and calcitonin, which reduce bone resorption.2-4 Here we consider whether teriparatide offers any worthwhile advantages over these other options.
article type
publisher identifier
  • dtdt0412
Alternative Title
  • ▼Teriparatide for postmenopausal osteoporosis
is part of this journal
PubMed ID
  • 15587764



Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata